| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Numinus Wellness (OTC:NUMIF) with support from the Multidisciplinary Association for Psychedelic Studies (MAPS) will utilize Optimi Health’s (OTC:OPTHF) Good Manufacturing Practice (GMP)-compliant MDMA to conduct a therapist-experiential training program.
To be conducted in Canada, the approval-pending clinical trial will provide practitioners with training in MDMA-assisted therapy including the possibility of experiencing and observing MDMA sessions to further their understanding of psychedelic-assisted therapy.
Optimi CEO Bill Ciprick says the company is thrilled to participate in the project, which he says will allow therapists the ability to provide “a greater standard of care” to patients undergoing psychedelic-assisted treatments.
Numinus founder and CEO Payton Nyquvest sees the partnership as one that “opens the doors to a groundbreaking opportunity for psychedelic therapists worldwide,” pioneering a new era of research and access to MDMA-assisted therapy by “empowering therapists to unlock transformative healing journeys for their clients.”
Meanwhile, MDXX-class molecules company PharmAla Biotech Holdings (OTC:PMBHF) has received a permit to export its proprietary, also GMP-compliant MDMA LaNeo to the University of Sydney.
The shipment marks the fulfillment of prior August’s $125,000 contract between the parties.
CEO Nick Kadysh stated PharmAla’s intention to deliver more shipments to its partners around the world soon, particularly in Australia where the running of the TGA’s regulatory changes that will allow for the prescription of MDMA and psilocybin treatments under the Authorized Prescriber Scheme will begin in just two weeks.
See also: Creso Pharma's LOI For Import Of Swiss MDMA And Psilocybin Therapeutics To Australia
The contract’s fulfillment has actually constituted a “material change” under applicable securities law, so the company announced it is discontinuing a non-brokered private placement consisting of up to 16,666,666 units for aggregate gross proceeds of up to $3.79 million (CA$5).
Photo: Benzinga edit with photo by Pexels.
